CONGRESSES
CONGRESSES
Find information on previous and upcoming congresses
View upcoming congresses and filter through abstracts, presentations, and posters from past congresses.
Upcoming congresses
Eastern Allergy Conference
BioCryst will attend the 2026 Eastern Allergy Conference from May 28 – May 31, 2026.
Visit the Congress Website for More Information
MSAAI
BioCryst will attend the 2026 MSAAI on June 06, 2026.
European Academy of Allergy and Clinical Immunology (EAACI) Congress
BioCryst will attend the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress from June 12 – June 15, 2026.
Browse our archive of congress materials
Filter
Showing 131 Materials
-
Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
AAAAI | 2026 | HAE -
Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial
AAAAI | 2026 | HAE -
Navenibart Delays Time to First Attack in Hereditary Angioedema: Results from ALPHA-STAR
AAAAI | 2026 | HAE -
Real-World Attack Rate Reductions After Berotralstat Initiation Among Patients with Hereditary Angioedema with Normal C1-Inhibitor Stratified by Prior Long-Term Prophylaxis
AAAAI | 2026 | HAE -
Impact of Berotralstat on Hereditary Angioedema Attack Rates in Patients with C1-Inhibitor Deficiency: Real-World Evidence Stratified by Prior Long-Term Prophylaxis
AAAAI | 2026 | HAE -
Impact of Berotralstat on Healthcare Resource Utilization in Patients with Hereditary Angioedema\ with Normal C1-Inhibitor
AAAAI | 2026 | HAE -
Reductions in Healthcare Resource Utilization Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency Following the Initiation of Berotralstat
AAAAI | 2026 | HAE -
Medication Routines Among Patients With Hereditary Angioedema
AAAAI | 2026 | HAE -
Oral Berotralstat Reduces the Rate of Moderate and Severe Attacks and Percentage of Days with HAE Symptoms Over 48 Weeks in Children Aged 2 to Less Than 12 Years: Interim Data from APeX-P
AAAAI | 2026 | HAE -
Oral Berotralstat Reduces Hereditary Angioedema Attack Rates in Pediatric Patients Aged 2 to <12 Years Without Long-Term Prophylaxis During the 12-Week Standard of Care Period: Interim Data from the APeX-P Study
WSAAI | 2026 | HAE